Search results for: Pricing and Reimbursement
Filter search results
Spotlight on OHE: Value Based Pricing and New Technologies
31 December 2012
…presentation (see below) discussed methods and processes for coordinating the assessment of diagnostics and treatments and urged that a consistent approach be developed and implemented. This was based in part…
Payment Models for Multi-Indication Therapies
1 November 2021
…Available from https://www.ohe.org/publications/multi-indication-pricing-mip-practical-solutions-and-steps-move-forward. Towse, A., Cole, A., and Zamora, B. (2018) The Debate on Indication-Based Pricing in the U.S. and Five Major European Countries. OHE Consulting Report. Available from https://www.ohe.org/publications/debate-indication-based-pricing-us-and-five-major-european-countries….
A global landscape analysis of access to tumour-agnostic therapies
1 December 2025
…TA therapies – pembrolizumab, larotrectinib, and entrectinib – to assess regulatory, health technology assessment (HTA), and reimbursement outcomes and identify barriers and possible solutions along the access pathway. The key…
A Framework for Value-aligned Pricing of Combination Therapies
25 June 2024
…development of combination therapies becoming more common in oncology and beyond, and a lack of agreed-upon pricing models in Europe, the need for innovative pricing strategies is increasingly evident. The…
The Spanish Medicines Market Today
9 February 2011
…market authorisation, pricing and reimbursement for medicines still are decided at national level, regions have been implementing their own policies intended to affect demand and shape the market. The change…
Is Rate Of Return Pricing A Useful Approach When Value-Based Pricing Is Not Appropriate?
22 March 2019
…in the United States: Pricing and Paying for Cures. OHE Seminar Briefing 25. RePEc. Marsden, G. and Towse, A., 2017. Exploring the Assessment and Appraisal of Regenerative Medicines and Cell Therapy Products:…
A NICE Wind of Change? The What and So What of the NICE Methods Consultation
7 December 2020
…in England and beyond. These are described and recommended on in our recently published report (Rodes Sanchez, Henderson and Steuten, 2020). In conclusion, NICE proposed changes to address a number…
Join OHE at ISPOR: MCDA, Risk Sharing and Value-Based Pricing
4 October 2011
…of a Centralized European Pricing and Reimbursement Agency,’ moderated by Mark Schulpher, University of York, and including also Hans-Georg Eichler, EMA. Should an agency similar in structure to EMA be…
Altering the trajectory of HIV in Europe
22 May 2025
…language, and are targeted at both general populations and healthcare professionals, have the potential to educate and reduce prejudice and stigma. Diversifying treatment options: PrEP and antiretroviral therapy (ART) are…